Medifast (MED) Capital Expenditures (2010 - 2026)

Medifast has reported Capital Expenditures for 17 years, with the latest figure at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 27.99% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.2 million (down 27.29% YoY), and the FY2025 full-year result was $5.6 million, down 24.68% from the prior year.
• Capital Expenditures for Q1 2026 stood at $1.1 million, down from $1.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $9.1 million in Q4 2022, with the low at $946000.0 in Q4 2023.
• Historically, Capital Expenditures has averaged $2.2 million across 5 years, with a median of $1.7 million in 2023.
• Annual changes were most pronounced in 2023 — Capital Expenditures sank 89.56% — and 2024, when it surged 141.54%.
• Medifast's Capital Expenditures stood at $9.1 million in 2022, then slumped by 89.56% to $946000.0 in 2023, then surged by 141.54% to $2.3 million in 2024, then slumped by 40.88% to $1.4 million in 2025, then declined by 18.87% to $1.1 million in 2026.
• The last three Capital Expenditures figures came in at $1.1 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.